Bosera Hang Seng SCHK Innovative Drug Select ETF (520690)
- 0.759
- +0.006+0.80%
Bosera Hang Seng SCHK Innovative Drug Select ETF (520690) News
Day One of the 2026 National Reimbursement Drug List Negotiations: Representatives from Multiple Companies Display Visible Joy as Traditional Chinese Medicine and Chronic Disease Drugs Take Center Stage
The annual national medical insurance catalog negotiations have once again entered the stage of on-site bargaining.
Key Pre-Market News for A-Shares (2026-08-28)
Mini Program: Key Pre-Market News for A-Shares Important News 1. Ministry of Finance: Continue to deepen zero-based budgeting reform, strengthen local government debt management, and optimize the allocation of fiscal resources. On August 26, the Ministry of Finance held a seminar on scientific fiscal management in Hefei, Anhui Province, to study and deploy measures for advancing scientific fiscal management. Lan Foan, Secretary of the Leading Party Members Group and Minister of the Ministry of Finance, attended and delivered remarks. The meeting emphasized the following: First, place greater emphasis on improving efficiency by continuing to deepen zero-based budgeting reform, strengthening performance orientation, enhancing local government debt management, and optimizing the allocation of fiscal resources; Second, place greater emphasis on strengthening coordination, including coordination of budgets and existing resources,
Shares surged more than 16% following the earnings release; what is driving Hansoh Pharmaceutical's growth?
Revenue growth from innovative drugs is not dependent on a proportional increase in selling expenses, while the advancement of overseas clinical trials enhances the likelihood of achieving milestones and realizing sales royalties from collaborative projects.
BeiGene's H1 net profit surges 386% year-on-year, driven by Brukinsa as revenue surpasses $3.2 billion | Financial Report Insights
BeiGene’s performance in the first half of 2026 significantly surpassed the same period last year, with a marked improvement in profitability, validating the effectiveness of its commercialization strategy. According to the company’s announcement, for the six months ended June 30, 2026, BeiGene’s total revenue increased by 32.3% year-on-year to USD 3.219 billion, while net profit surged by 385.8% year-on-year to USD 464 million, accelerating the release of operating leverage effects. Diluted earnings per ADS rose substantially from USD 0.85 in the same period last year to USD 4.01. The core driver was strong demand for its flagship product, Brukinsa (zanubrutinib), in the U.S. and European markets. During the same period, the company’s non-
Since the second half of the year, 47 companies listed on the STAR Market have been surveyed by foreign institutional investors, with five industry leaders drawing particular attention | Review
① In terms of the aggregate volume over the past two months, Beigene, Montage Technology, Espressif Systems, ACM Research Shanghai, and Segway-Ninebot were the STAR Market companies that attracted the most attention from foreign institutional investors; ② A deeper examination of the due diligence conducted by these foreign institutions reveals a key question: within the context of the global AI cycle and supply chain restructuring, can these companies translate their "technology narrative" into tangible orders, gross margins, and cash flow?
Following the commercial launch of mRNA cancer vaccines, which innovative drug sectors are poised for a "GPT moment"?
1. mRNA technology has made its first breakthrough from preventive vaccines into the field of oncology treatment, with brokerage firms hailing it as the "GPT moment" for cancer vaccines; 2. The 2026 WCLC and ESMO annual congresses will be held in Seoul, South Korea, and Madrid, Spain, respectively; 3. It is reported that three ADCs will be featured in late-breaking abstract oral presentations at the WCLC congress, while second-generation immuno-oncology (IO) therapies are also expected to gain significant visibility.
Moderna achieves first success with its "personalized mRNA vaccine," while China's innovative drugs are also in the pipeline.
Moderna’s Phase III clinical trial has, for the first time in a large-scale study, validated the oncological therapeutic value of its personalized mRNA cancer vaccine, with Citi highlighting Chinese companies positioned to benefit. Hengrui’s subsidiary Ruihongdi has advanced its candidate RGL-270 into Phase II trials, reporting promising data for pancreatic cancer; CSPC’s SYS6026 is progressing steadily with a controlled design; while Akeso, Yunding, and CanSino each hold differentiated competitive advantages. The race among Chinese firms to develop mRNA cancer vaccines has officially begun.
ETF Market Moves | Healthcare ETFs Surge Across the Board; Vaccine ETFs from China Merchants Fund and Harvest Fund Hit 10% Daily Limit
Gelonghui, August 20 – Merck & Co and Moderna announced that their jointly developed melanoma skin cancer vaccine achieved positive preliminary results in its first late-stage clinical trial, triggering a broad surge in pharmaceutical ETFs in the A-share market. Specifically, the China Merchants Vaccine ETF and Harvest Vaccine ETF hit the 10% daily limit up, while the Fullgoal Vaccine ETF, Penghua Vaccine ETF, and Guotai Vaccine ETF rose by more than 8%. The Guotai ChiNext Pharmaceutical ETF and HuaAn Biopharmaceutical ETF gained over 7%, alongside the HuiTianFu Biopharmaceutical ETF, TianHong Biopharmaceutical ETF, Penghua STAR Market Pharmaceutical ETF, and China AMC STAR Market Pharmaceutical ETF. Also mentioned were the Hong Kong Stock Connect Innovative Drug Healthcare and Nasdaq Biotechnology...
Cailian Press Venture Capital Channel: Total financing in the primary market reached approximately RMB 10.6 billion this week, a 25% increase from the previous week; Qianheyibang completed its Series B funding round of over RMB 2 billion.
1. This week (August 8–14), there were 134 investment and financing events in China, a week-on-week decrease of 10.67%; the total disclosed financing amount was approximately RMB 10.59 billion, a week-on-week increase of 25.19%. 2. Sectors such as advanced manufacturing and artificial intelligence were relatively active, with advanced manufacturing recording the highest total disclosed financing of approximately RMB 2.65 billion. 3. Qianheyibang completed its Series B financing round of over RMB 2 billion, marking the largest single investment deal disclosed this week.
Shanghai Industrial Capital’s RMB 1.5 Billion Phase II Fund Successfully Closed! Exclusive Interview with Liu Dawei on Decoding Investment "Blind Boxes"
① With the recent completion of the first closing of the Shanghai Biopharmaceutical Fund Phase II, raising RMB 1.5 billion, Shanghai Industrial Capital has effectively established a closed-loop investment framework covering the entire lifecycle of the biopharmaceutical sector. ② Each fund employs distinct strategies. As Liu Dawei stated, “Appetizers, hot soups, and desserts are prepared separately, with each dish requiring precise control of heat.” ③ Liu Dawei also provided insights into the future outlook and trends of the vaccine industry.
CRO Outperforms CPO in August: Is a Rally in Pharmaceutical Stocks Next After the Optical Module Surge?
① The semi-annual report indicates that the operating performance and order backlog of multiple CRO companies have resumed rapid growth, driven by a robust recovery in client demand; ② In Q2, fund allocations to the pharmaceutical sector overall dropped to historic lows, yet innovative drugs and CROs emerged as the primary areas for contrarian accumulation by capital at market bottoms; ③ The CDMO sub-sector has entered a critical period for new contract signings and the volume ramp-up of major overseas products.
Spring for Non-Tech Sectors? Pharmaceutical Sector Surpasses Semiconductors in Research Interest
① Last week, the pharmaceutical and biotechnology sector received 104 visits from public mutual fund institutions for research purposes, ranking first among all SW1 sectors, with nearly double the number of visits compared to the second-ranked sector. ② The sector’s valuation remains at a relatively low level and offers ample growth potential, making it attractive for portfolio allocation and prompting multiple public mutual fund institutions to actively conduct research. ③ The sector may face risks of volatility and divergence, and investors should avoid blind investment.
Innovative pharmaceuticals and the CDMO sector attract intensive institutional research visits, with ESMO-disclosed data and overseas business development progress drawing attention.
① During this week (August 3 to August 9), a total of 57 A-share companies received institutional investor visits. ② Among them, BeiGene received the highest number of visits, hosting 207 institutions. ③ Zelgen Biopharmaceuticals and Zhejiang Jiuzhou Pharmaceutical ranked among the top ten listed companies by number of visiting institutions, with 97 and 77 institutions respectively.
Express News | Most Hong Kong-listed innovative drug stocks rose, with Zai Lab surging over 14%, Wuxi Bio gaining more than 6%, Wuxi Apptec rising nearly 6%, and Ascletis Pharma and Confo Therapeutics each climbing over 4%.
First-half net profit surges by several-fold, overseas licensing deals hit record highs, and more than RMB 4 billion in losses reversed—multiple innovative drugmakers report explosive earnings growth.
① BeiGene has anchored its full-year operating profit at the billion-dollar level; RemeGen achieved a significant turnaround through a major BD licensing deal with AbbVie; Innovent’s GLP-1 and other new pipelines are stepping in to drive growth. ③ Industry narratives are shifting from ‘pipeline storytelling’ to performance realization, with policy support and a surge in outbound BD deals accelerating the validation of commercialization closed loops.
BeiGene reported a 30% year-over-year revenue increase and a 151% surge in net profit for Q2, raising its full-year revenue guidance to $6.6–6.8 billion.
More updates to follow.
Nine consecutive limit-up "speculative stock": trading halt review completed; resumes trading tomorrow! | Selected Post-Market Announcements
The nine-limit-up "speculative stock" will resume trading starting tomorrow! The "innovative drug leader" reported a 151% year-over-year surge in net profit for Q2; a major photovoltaic company will be removed from the special treatment list and halt trading for one day...
Results of the 12th batch of national centralized procurement announced, with leading manufacturers securing major orders.
① All 65 products were successfully procured, with 327 companies and 521 products provisionally selected; ② Competitive dynamics for several high-profile products have been reshaped, with leading enterprises securing a larger share of provisional selections, and procurement rules further optimized; ③ The 'anti-grind' (anti-excessive competition) mechanism is showing initial effectiveness, as centralized procurement shifts from price-driven competition toward comprehensive capability assessment.
The STAR Market experienced a sharp correction in July—Which stocks served as safe havens?
① Excluding newly listed stocks from the past month, 97 out of the 610 STAR Market companies posted gains during the month despite broader market weakness. ② The biopharmaceutical sector demonstrated notable resilience in this market correction, with the segment posting an average decline of only -4.35%. ③ Guojin Securities stated that current market valuations fail to adequately reflect business development (BD) potential, and pipeline internationalization will underpin long-term industrial evolution for pharmaceutical companies.
Live Coverage of the 12th Batch of National Drug Procurement Bidding: Companies Strategically Navigate the New 'Resurrection' Rules Through Precise Calculations
① A total of 495 companies, presenting 859 products, engaged in fierce competition, as the market—worth nearly RMB 60 billion—saw intense on-site bidding; ② On-site company representatives noted that pricing in this round has become more challenging, shifting away from a singular focus on the lowest price toward a balanced assessment of selection probability and market potential; ③ Multiple experts pointed out that the new rules are expected to reduce abnormally low-price competition and encourage pharmaceutical companies to compete based on product quality and overall capabilities.